SECURITIES AND EXCHANGE COMMISSION
                       Washington, D.C. 10549
                             FORM 10QSB/A



(Mark One)

[x]    Quarterly report under Section 13 or 15(D) of the Securities
       Exchange Act of 1934

            For the quarterly period ended June 30, 1999

[ ]    Transition report under Section 13 or 15(D) of the Exchange Act

            For the transition period from _________ to _________


Commission file number 0-15888


                        IGENE Biotechnology, Inc.
  _________________________________________________________________
  (Exact name of Small Business Issuer as Specified in its Charter)


          Maryland                              52-1230461
_______________________________         ___________________________
(State or Other Jurisdiction of         (I.R.S. Employer
 Incorporation or organization)          Identification No.)


         9110 Red Branch Road, Columbia, Maryland 21045-2024
         ___________________________________________________
              (Address of Principal Executive Offices)

                           (410) 997-2599
          ________________________________________________
          (Issuer's Telephone Number, Including Area Code)

                                 None
        ____________________________________________________
        (Former Name, Former Address and Former Fiscal Year,
                    if Changed Since Last Report)



Check whether the Issuer: (1) filed all reports required to be filed
by Section 13 or 15(D) of the Exchange Act during the past 12 months
(or for such shorter period that the registrant was required to file
such reports), and (2) has been  subject to such filing requirements
for the past 90 days.

Yes       x              No
	________                ________


State  the  number  of  shares  outstanding of each of  the issuer's
classes of common equity, as of the latest practicable date:
34,427,507 as of July 26, 1999.

Traditional Small Business Disclosure Format (check one):

Yes                      No       x
      ________                ________



                           SIGNATURES

In accordance with the requirements of the Exchange  Act, the
registrant caused this report to be signed on its  behalf  by
the undersigned, thereunto duly authorized.



                          IGENE Biotechnology, Inc.
                          (Registrant)



Date July 30, 1999        /s/Stephen F. Hiu
                          ___________________________________
                          Stephen F. Hiu
                          President and Treasurer
                          (On behalf of the Registrant and as
                          Principal Financial Officer)